La Jolla Pharmaceutical (LJPC) Stock Forecast, Price & News

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LJPC. TheStreet upgraded shares of La Jolla Pharmaceutical from a "d+" rating to a "c-" rating in a research note on Friday, July 29th. StockNews.com assumed coverage on shares of La Jolla Pharmaceutical in a report on Friday, July 15th. They issued a "hold" rating for the company.

La Jolla Pharmaceutical Price Performance

NASDAQ:LJPC remained flat at $6.20 during trading on Friday. 73,611 shares of the company's stock were exchanged, compared to its average volume of 544,103. The stock has a market cap of $154.57 million, a price-to-earnings ratio of 41.33 and a beta of 2.39. La Jolla Pharmaceutical has a 52-week low of $3.07 and a 52-week high of $6.22. The company has a 50 day moving average of $4.57 and a 200 day moving average of $4.33.

La Jolla Pharmaceutical (NASDAQ:LJPC - Get Rating) last issued its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.16). La Jolla Pharmaceutical had a negative return on equity of 7.27% and a net margin of 10.08%. The firm had revenue of $10.43 million for the quarter, compared to the consensus estimate of $13.10 million. As a group, research analysts anticipate that La Jolla Pharmaceutical will post 0.04 earnings per share for the current fiscal year.